Receptors, Tumor Necrosis Factor, Type I
"Receptors, Tumor Necrosis Factor, Type I" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A tumor necrosis factor receptor subtype that has specificity for TUMOR NECROSIS FACTOR ALPHA and LYMPHOTOXIN ALPHA. It is constitutively expressed in most tissues and is a key mediator of tumor necrosis factor signaling in the vast majority of cells. The activated receptor signals via a conserved death domain that associates with specific TNF RECEPTOR-ASSOCIATED FACTORS in the CYTOPLASM.
| Descriptor ID |
D047888
|
| MeSH Number(s) |
D12.776.543.750.690.750 D12.776.543.750.705.852.760.597
|
| Concept/Terms |
Receptors, Tumor Necrosis Factor, Type I- Receptors, Tumor Necrosis Factor, Type I
- Receptors, Tumor Necrosis Factor, Member 1A
- TNFR p60
- TNFR-I
- Tumor Necrosis Factor Receptor Type I
- TNFR1
- Tumor Necrosis Factor Receptor 1A
- TNFRSF1A (Tumor Necrosis Factor Receptor Superfamily, Member 1A)
- Tumor Necrosis Factor Receptor Type 1
- Antigens, CD120a
- CD120a Antigens
- TNFRSF1A Receptor
- Receptor, TNFRSF1A
- Tumor Necrosis Factor Receptor Superfamily, Member 1A
- CD 120a Antigen
- 120a Antigen, CD
- Antigen, CD 120a
- CD120a Antigen
- Antigen, CD120a
|
Below are MeSH descriptors whose meaning is more general than "Receptors, Tumor Necrosis Factor, Type I".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Membrane Proteins [D12.776.543]
- Receptors, Cell Surface [D12.776.543.750]
- Receptors, Death Domain [D12.776.543.750.690]
- Receptors, Tumor Necrosis Factor, Type I [D12.776.543.750.690.750]
- Receptors, Immunologic [D12.776.543.750.705]
- Receptors, Cytokine [D12.776.543.750.705.852]
- Receptors, Tumor Necrosis Factor [D12.776.543.750.705.852.760]
- Receptors, Tumor Necrosis Factor, Type I [D12.776.543.750.705.852.760.597]
Below are MeSH descriptors whose meaning is more specific than "Receptors, Tumor Necrosis Factor, Type I".
This graph shows the total number of publications written about "Receptors, Tumor Necrosis Factor, Type I" by people in this website by year, and whether "Receptors, Tumor Necrosis Factor, Type I" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 3 | 0 | 3 |
| 2011 | 0 | 1 | 1 |
| 2013 | 1 | 1 | 2 |
| 2014 | 1 | 0 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 6 | 6 | 12 |
| 2018 | 8 | 8 | 16 |
| 2019 | 0 | 3 | 3 |
| 2020 | 0 | 3 | 3 |
| 2021 | 1 | 1 | 2 |
| 2022 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Receptors, Tumor Necrosis Factor, Type I" by people in Profiles.
-
Distinctive Biomarker Features in the Endotheliopathy of COVID-19 and Septic Syndromes. Shock. 2022 01 01; 57(1):95-105.
-
Severe COVID-19 Patients Show an Increase in Soluble TNFR1 and ADAM17, with a Relationship to Mortality. Int J Mol Sci. 2021 Aug 05; 22(16).
-
Increased Serum Levels of Soluble TNF-a Receptor Is Associated With ICU Mortality in COVID-19 Patients. Front Immunol. 2021; 12:592727.
-
Levels of Soluble CD14 and Tumor Necrosis Factor Receptors 1 and 2 May Be Predictive of Death in Severe Coronavirus Disease 2019. J Infect Dis. 2021 03 03; 223(5):805-810.
-
An immune-based biomarker signature is associated with mortality in COVID-19 patients. JCI Insight. 2021 01 11; 6(1).
-
Characterization of the Inflammatory Response to Severe COVID-19 Illness. Am J Respir Crit Care Med. 2020 09 15; 202(6):812-821.
-
Prevalence of phenotypes of acute respiratory distress syndrome in critically ill patients with COVID-19: a prospective observational study. Lancet Respir Med. 2020 12; 8(12):1209-1218.
-
Emerging pharmacological therapies for ARDS: COVID-19 and beyond. Intensive Care Med. 2020 12; 46(12):2265-2283.
-
Physician Judgment and Circulating Biomarkers Predict 28-Day Mortality in Emergency Department Patients. Crit Care Med. 2019 11; 47(11):1513-1521.
-
Immunological and Neurometabolite Changes Associated With Switch From Efavirenz to an Integrase Inhibitor. J Acquir Immune Defic Syndr. 2019 08 15; 81(5):585-593.